CDC shrinks childhood vaccine recommendation list to mirror “peer nations”
The US Centers for Disease Control (CDC) has shifted its stance on childhood vaccination, having minimised its routine recommendation list …
Post
-
-
Takeda and Protagonist seek FDA approval for rusfertide to treat PV
Takeda and Protagonist Therapeutics have jointly submitted a new drug application (NDA) seeking approval from the US Food and Drug …
-
Aktis Oncology kicks 2026 IPO cycle off with $210m target
The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a …
-
Podcast: Healthcare’s biggest 2025 trends and 2026 predictions
As the healthcare industry embarks on a new year, there are several factors that look set to impact pharmaceutical and …
-
Arrowhead receives Health Canada authorisation for Redemplo to treat FCS
Arrowhead Pharmaceuticals has received authorisation from Health Canada for its small interfering RNA (siRNA) medicine, Redemplo (plozasiran), as an adjunct …
-
Sanofi and Earendil Labs forge $2.56bn autoimmune deal
Ahead of JP Morgan 2026, pharmaceutical giant Sanofi has inked another deal with Helixon Therapeutics-affiliated startup Earendil Labs, which will …
-
Insilico and Servier announce $888m oncology research agreement
Insilico Medicine has entered a multi-year research and development (R&D) collaboration with Servier, worth up to $888m, to develop and …
-
Biogen’s Tysabri to be used on England’s NHS for highly active MS
The National Institute for Health and Care Excellence (NICE) has recommended natalizumab as an option for adults with highly active …
-
Samsung Bioepis initiates Byooviz commercialisation in Europe
Samsung Bioepis has started direct commercialisation of Byooviz, a biosimilar to Genentech’s Lucentis (ranibizumab), in Europe. The company has assumed commercial …
-
Valneva takes back charge of chikungunya vaccine supply in Asia
Valneva and the Serum Institute of India (SII) have ended a license agreement for chikungunya vaccine supply in Asia after …
-
China releases 2025 NRDL and first commercial insurance drug list
In early December, the 2025 updates of China’s National Reimbursement Drug List (NRDL) were finalised with a total of 114 …
-
Outlook Therapeutics receives FDA response on ONS-5010 for wet AMD
Outlook Therapeutics has received the US Food and Drug Administration’s (FDA) complete response letter (CRL) regarding the biologics licence application …
-
FDA approves Vanda Pharmaceuticals’ motion sickness drug Nereus
The US Food and Drug Administration (FDA) has approved Vanda Pharmaceuticals’ Nereus (tradipitant) for the prevention of vomiting induced by …
-
Emmaus, NIT sign Endari distribution agreement
Emmaus Life Sciences has entered into a licensing and exclusive distribution agreement with NeoImmuneTech (NIT) for Endari, a prescription-grade L-glutamine …
-
Genmab shelves Phase III lung cancer candidate
Genmab has discontinued development of acasunlimab, a bispecific antibody that was in mid and late-stage trials for solid tumours, including …
